In a laboratory at Ruhr University Bochum, Klaus Gerwert and his son Grischa have engineered a blood test that could fundamentally change how Alzheimer's and Parkinson's disease are detected—catching them years or even decades before the first tremor or forgotten name ever appears.
The test is based on immuno-infrared sensor technology, a platform that isolates misfolded proteins directly from blood using specific antibodies and then analyzes them with infrared spectroscopy and quantum cascade lasers. This approach detects the signature of protein misfolding that signals the earliest stages of neurodegeneration, long before the brain damage becomes irreversible. It's a stark departure from today's reality: modern diagnoses are made only when symptoms emerge, by which time the brain has already suffered massive, permanent injury. Yet for the first time, medications now exist that can actually slow Alzheimer's progression, and effective therapies are available for Parkinson's—but only if caught early enough.
The scientific challenge was formidable. The blood contains countless molecules, and the biomarkers researchers need to detect—amyloid beta for Alzheimer's, alpha-synuclein for Parkinson's—exist in minuscule amounts within that biochemical noise. The team solved this through an interdisciplinary combination of molecular biology, biophysics, and laser spectroscopy. They developed patented surface chemistry to anchor the antibodies to the sensor, created a blocking layer to prevent false signals, and then used difference spectroscopy to isolate the exact infrared signature of misfolded proteins from the complex background of body fluids. "These unique measurements are possible because of the combination of molecular biology, biophysics, and laser spectroscopy," says lead author Dr. Grischa Gerwert.
The significance is both immediate and profound. In aging societies, cases of these diseases are rising dramatically, straining health care systems and devastating families. Early detection through a simple blood test could enable preventive treatment before symptoms take hold. What makes this technology particularly promising is its scalability: quantum cascade laser technology allows for parallel measurements, meaning the same principle could eventually screen entire populations efficiently and affordably.
The research, published April 24, 2026, on the cover of the Journal of Physical Chemistry B, is not merely theoretical. Gerwert's company BetaSENSE is already deploying the immuno-infrared sensor in clinical studies on behalf of pharmaceutical companies, including testing a vaccine against Parkinson's disease. The sensor has proven itself in real-world research conditions.
The path from laboratory to clinic remains challenging. European IVDR Regulation approval is required before the test can become a standard early detection tool for the general public—a process that demands considerable regulatory effort and financial investment. But the momentum is building. "At BetaSENSE, we are working hard to advance the approval process and make the test available to the public as soon as possible," says Grischa Gerwert. For people at risk of these devastating diseases, and for the families and health systems that support them, a simple blood test that catches the disease before symptoms appear could represent the difference between a life lived fully and one shadowed by neurodegeneration. The technology exists. The question now is how quickly it can reach those who need it.